UNSPSC 51313116: Chlorcyclizine pamoate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C23H16O6.C18H21ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73R47NSS6P, chemically known as 2-naphthalenecarboxylic acid, 4,4'-methylenebis 3-hydroxy-, compd. with 1-((4-chlorophenyl)phenylmethyl)-4-methylpiperazine, but more generally known as chlorcyclizine pamoate, which bears US NIH Compound Identifier 24296.

European Medicines Agency schedules chlorcyclizine pamoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06178MIG. Most nations, for tariff purposes, schedule chlorcyclizine pamoate under HS 29335995. SMILES: CN1CCN(CC1)C(C2CCCCC2)C3CCC(CC3)CL.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.

UNSPSC 51313116 Chlorcyclizine pamoate is a Commodity code that in practice captures state and local procurement of pharmaceuticals and related health products, though recent solicitations under this code show minimal specificity to the code's nominal product and instead reflect broader pharmaceutical supply contracting. State and local health departments, multi-state cooperative purchasing alliances, and county health agencies solicit under this code for generic and branded pharmaceuticals, over-the-counter products, naloxone, and drug deactivation systems. The work spans direct manufacturer agreements, multi-source generic pharmaceutical supply through authorized wholesalers, and emergency health product procurement. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and regional cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon).

Recent activity shows geographic concentration in Florida and Texas, with broader multi-state participation through cooperative purchasing mechanisms. The Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802), due March 26, 2026, sought manufacturers to supply identified products through three authorized wholesalers with pricing weighted 75 percent on competitiveness and compliance requirements including current Good Manufacturing Practices and Drug Supply Chain Security Act certification. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler arrangements. Vendors must typically maintain substantial insurance coverage, comply with E-Verify and federal drug-supply requirements, and accept administrative fees or performance penalties on contract volumes.